+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07639450

Evaluating N-3C01 Alone and With PD-L1 Antibody in Advanced Malignant Solid Tumors A Phase III Safety and Efficacy Study

Led by Hefei Xinzhu Biological Technology Co., Ltd. · Updated on 2026-09-17

114

Participants Needed

6

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of N-3C01, given as a subcutaneous injection, either alone or combined with a PD-L1 monoclonal antibody, in adults with advanced malignant solid tumors. This Phase III study includes a dose escalation phase for both monotherapy and combination therapy, followed by a cohort expansion phase for the combination treatment. Participants will receive N-3C01 injections every 2 or 3 weeks. Some participants with selected tumor types will also receive pembrolizumab, an intravenous PD-L1 monoclonal antibody, alongside N-3C01. During Phase I, different doses and schedules will be tested to find the maximum tolerated dose and recommended Phase II dose. In Phase II, participants will receive the recommended dose of N-3C01 combined with a fixed dose of the PD-L1 antibody. Participants will be closely monitored through safety assessments including vital signs, ECGs, blood tests, and urinalysis up to about 24 months. Researchers will track adverse events, dose-limiting toxicities, and treatment effects on tumors. Pharmacokinetics and immune responses will also be measured. The study involves regular visits for treatment and safety follow-up to ensure thorough monitoring throughout the trial.

CONDITIONS

Brief Title

N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

Research Team

K

Karen Zhou

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here